Current Report Filing (8-k)
December 22 2022 - 09:01AM
Edgar (US Regulatory)
0001174940 false 0001174940 2022-12-22
2022-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report:
December 22, 2022
(Date
of earliest event reported)
Oragenics, Inc.
(Exact
name of registrant as specified in its charter)
|
FL |
|
001-32188 |
|
59-3410522 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
|
4902 Eisenhower Boulevard,
Suite 125
Tampa,
FL
|
|
33634 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock |
|
OGEN |
|
NYSE American |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 OTHER EVENTS.
On
December 22, 2022, Oragenics, Inc. issued a press release
announcing favorable results from its ongoing Good Laboratory
Practice toxicology study to evaluate the safety and immunogenicity
of its NT-CoV2-1 intranasal vaccine candidate. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
In
accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized on this 22nd day
of December, 2022.
|
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
|
|
BY: |
/s/
Kimberly Murphy |
|
|
|
Kimberly
Murphy
President
and Chief Executive Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From May 2023 to Jun 2023
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2022 to Jun 2023
